Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 4/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962444 | 0.91 | SGK1 (0.61) | SGK1SLC22A12MEN1KMT2AMAP2K4 | |
| SCHEMBL3964290 | 0.91 | ALDH1A1 (0.53) | SGK1MEN1KMT2AMAP2K4MAPK8 | |
| SCHEMBL3969461 | 0.91 | MEN1 (0.53) | SGK1MEN1KMT2AMAP2K4MAPT | |
| SCHEMBL3966336 | 0.91 | SGK1 (0.51) | SGK1MEN1KMT2AMAP2K4MAPK8 | |
| SCHEMBL3968048 | 0.89 | MAP2K4 (0.53) | SGK1MAP2K4MAPTKDM4EALDH1A1 | |
| SCHEMBL3968707 | 0.88 | MAP2K4 (0.47) | SGK1MAP2K4MAPK8MAPK10MAPK14 | |
| SCHEMBL3964181 | 0.87 | SGK1 (0.57) | SGK1MEN1KMT2AMAP2K4MAPK8 | |
| SCHEMBL3966356 | 0.87 | PKM (0.56) | SGK1SLC22A12MEN1KMT2AMAP2K4 | |
| SCHEMBL3966277 | 0.86 | SMN1; SMN2 (0.51) | SGK1MEN1KMT2AMAP2K4MAPK8 | |
| SCHEMBL3972626 | 0.86 | MAP2K4 (0.52) | SGK1MEN1KMT2AMAP2K4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101243051-A | P38 MAP kinase inhibitors and methods for using the same | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | CN | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | SGK1 457/4885SLC22A12 3212/4885MEN1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.